| Range: | 0.97-4.0 | Vol Avg: | 451348 | Last Div: | 0 | Changes: | 0.18 |
| Beta: | 1.01 | Cap: | 0.22B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue May 07 2019 | Empoloyees: | 27 | ||
| CUSIP: | 89532M101 | CIK: | 0001563880 | ISIN: | US89532M1018 | Country: | US |
| CEO: | Ms. Jennifer L. Good | Website: | https://www.trevitherapeutics.com | ||||
TRVI 2.98 Stock Price Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow